Get all your news in one place.
100's of premium titles.
One app.
Start reading
Barchart
Barchart
Kritika Sarmah

FOUND: Moderna earnings preview what to expect - What They Never Told You

Valued at $10.7 billion by market cap, Moderna, Inc. (MRNA) is a biotechnology company specializing in the development and commercialization of messenger RNA (mRNA) therapeutics and vaccines. The Cambridge, Massachusetts-based company is best known for its COVID-19 vaccine (mRNA-1273, branded as Spikevax), which was one of the first mRNA vaccines authorized for emergency use globally.

The healthcare major is expected to announce its third-quarter results on Thursday, Nov. 6. Ahead of the event, analysts expect Moderna to deliver a loss of $2.03 per share, down significantly from the profit of $0.03 per share reported in the year-ago quarter. On a positive note, the company has surpassed the Street’s bottom-line estimates in each of the past four quarters.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.